je.st
news
Onxeo: Belinostat Phase I/II Results in Soft Tissue Sarcoma to Be...
2015-04-10 00:14:21| Logistics - Topix.net
PARIS & COPENHAGEN, Denmark-- -- Regulatory News: Onxeo S.A. , an innovative company specializing in the development of orphan oncology drugs, today announced that the phase I/II clinical trial of belinostat in combination with doxorubicin in patients with soft tissue sarcoma was accepted for presentation in the Poster Discussion Session at the 2015 Annual Meeting of the American Society of Clinical Oncology , taking place in Chicago, USA from May 29 to June 2, 2015. The PXD101-CLN-14 study was an open -label, multicenter, dose-escalation phase I/II to evaluate the safety and efficacy of the combination of belinostat with doxorubicin in patients with advanced solid tumors and STS .
Tags: to
results
iii
soft
Category:Transportation and Logistics